Aldeyra Therapeutics, Inc. (ALDX)
After hours:
| Previous close | 3.9400 |
| Open | 3.9400 |
| Bid | 3.9100 x 200 |
| Ask | 3.9400 x 200 |
| Day's range | 3.8300 - 3.9750 |
| 52-week range | 1.4200 - 11.9700 |
| Volume | |
| Avg. volume | 588,009 |
| Market cap | 233.499M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.25 |
Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
LEXINGTON, Mass., April 25, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
ZacksIs Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
- Business Wire
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
LEXINGTON, Mass., April 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
